GCGR - glucagon receptor Gene
Species: Macaca fascicularis
Gene Type: protein coding
Gene ID: 102133101
GCGR Products (6)
| mRNA | Protein | Name |
|---|---|---|
| XM_045376476.1 | XP_045232411.1 | glucagon receptor isoform X1 |
| XM_045376478.1 | XP_045232413.1 | glucagon receptor isoform X3 |
| XM_045376480.1 | XP_045232415.1 | glucagon receptor isoform X5 |
| XM_045376479.1 | XP_045232414.1 | glucagon receptor isoform X4 |
| XM_045376477.1 | XP_045232412.1 | glucagon receptor isoform X2 |
| XM_045376481.1 | XP_045232416.1 | glucagon receptor isoform X6 |
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
glucagon receptor |
|
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
Bioactive Molecules
(10)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-13443 | Exendin-4 | Agonist | 99.89% | Unkown |
| HY-P0014 | Liraglutide | Agonist | 99.95% | Unkown |
| HY-112185 | Orforglipron | Agonist | 99.64% | Unkown |
| HY-P0082 | Glucagon (1-29), bovine, human | 99.91% | Unkown | |
| HY-P0120 | Dulaglutide | Agonist | 96% | Unkown |
| HY-P0082A | Glucagon (1-29), bovine, human hydrochloride | 99.89% | Unkown | |
| HY-13443A | Exendin-4 acetate | Agonist | 99.87% | Unkown |
| HY-112185A | Orforglipron hemicalcium hydrate | Agonist | 99.58% | Unkown |
| HY-P3469A | Dasiglucagon acetate | 98.66% | Unkown | |
| HY-P3469 | Dasiglucagon | Agonist | / | Unkown |
Clinical Phase
Bioactive Molecules
(17)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase
|
|---|---|---|---|---|
| HY-P3463 | Beinaglutide | 98.49% | Phase 4 | |
| HY-P0165 | Taspoglutide | Agonist | 99.43% | Phase 3 |
| HY-P2221B | Glepaglutide acetate | Agonist | 99.48% | Phase 3 |
| HY-P4146A | Survodutide TFA | Agonist | 99.39% | Phase 3 |
| HY-P2221 | Glepaglutide | Agonist | 99.70% | Phase 3 |
| HY-P3375A | Mazdutide TFA | Agonist | 99.67% | Phase 3 |
| HY-P3506B | Retatrutide acetate | Agonist | 99.69% | Phase 3 |
| HY-112668B | Retagliptin hydrochloride | / | Phase 3 | |
| HY-125824 | Danuglipron | Agonist | 99.85% | Phase 2 |
| HY-50663 | MK 0893 | Antagonist | 99.83% | Phase 2 |
| HY-19904 | Adomeglivant | Antagonist | 99.63% | Phase 2 |
| HY-P2231A | Cotadutide acetate | Agonist | 99.30% | Phase 2 |
| HY-12525 | LGD-6972 | Antagonist | 98.0% | Phase 2 |
| HY-19947 | PF-06291874 | Antagonist | 99.31% | Phase 2 |
| HY-P10018 | Bamadutide | Agonist | 99.94% | Phase 2 |
| HY-P3498 | Elsiglutide | Agonist | 99.64% | Phase 2 |
| HY-19374 | BAY-27-9955 | Antagonist | 99.68% | Phase 1 |
Bioactive MoleculesInhibitory Antibodies
(3)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase
|
|---|---|---|---|---|
| HY-P99383 | Volagidemab | Antagonist | ≥99.0% | Phase 2 |
| HY-P99357 | Crotedumab | Inhibitor | 99.22% | Phase 1 |
| HY-P992007 | PF-06293620 | Antagonist | / | Phase 1 |
Pre-clinical Phase
Bioactive Molecules
(154)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-P3506 | Retatrutide | Agonist | 99.96% | Unkown |
| HY-P3375 | Mazdutide | Agonist | 99.97% | Unkown |
| HY-P0054 | GLP-1(7-36), amide acetate | 99.01% | Unkown | |
| HY-P4146 | Survodutide | Agonist | 99.99% | Unkown |
| HY-121835 | GLP-1R agonist 2 | Agonist | 99.57% | Unkown |
| HY-P0054A | GLP-1(7-36), amide | Agonist | 99.90% | Unkown |
| HY-P1141 | GLP-1(9-36)amide | Antagonist | 99.69% | Unkown |
| HY-101116 | GLP-1R Antagonist 1 | Antagonist | 99.67% | Unkown |
| HY-P11274A | Zenagamtide sodium | Agonist | 99.96% | Unkown |
| HY-P3506A | Retatrutide TFA | Agonist | 99.47% | Unkown |
| HY-103546 | BETP | Agonist | 99.48% | Unkown |
| HY-P1024 | GLP-2(1-33)(human) | Agonist | 98.43% | Unkown |
| HY-P0054B | GLP-1(7-36), amide TFA | 98.82% | Unkown | |
| HY-P10736A | AMG133 peptide payload TFA | Agonist | 99.70% | Unkown |
| HY-P1023 | VIP(6-28)(human, rat, porcine, bovine) | Antagonist | 98.09% | Unkown |
| HY-P1160 | Bay 55-9837 | Agonist | 99.56% | Unkown |
| HY-P3366 | Ecnoglutide | Agonist | 99.93% | Unkown |
| HY-124622 | NNC-0640 | Modulator | 98.43% | Unkown |
| HY-P10736 | AMG133 peptide payload | 99.94% | Unkown | |
| HY-129658A | TT-OAD2 | Agonist | 99.59% | Unkown |
| HY-P3291 | Dapiglutide | Agonist | 98.52% | Unkown |
| HY-P2231 | Cotadutide | Agonist | 99.80% | Unkown |
| HY-142162 | LSN3318839 | Modulator | 99.22% | Unkown |
| HY-10930 | UNC0321 | Inhibitor | 99.91% | Unkown |
| HY-P2625 | GLP-2(3-33) | Agonist | 99.82% | Unkown |
| HY-P0150 | Glucagon (19-29), human | Inhibitor | 99.11% | Unkown |
| HY-P0014S1 | Liraglutide-13C5,15N tetraTFA | Agonist | 97.74% | Unkown |
| HY-P1144 | Oxyntomodulin (bovine, porcine) | Agonist | 99.77% | Unkown |
| HY-P3101 | GLP-1(28-36)amide | 99.18% | Unkown | |
| HY-P1145A | Glucagon-like peptide 1 (1-37), human TFA | Agonist | 99.55% | Unkown |
| HY-P1348 | GLP-1 moiety from Dulaglutide | 99.60% | Unkown | |
| HY-116819 | VU0453379 | Modulator | 98.0% | Unkown |
| HY-145632 | Pemvidutide | Agonist | 99.40% | Unkown |
| HY-N0630 | Shanzhiside methyl ester | Agonist | 99.97% | Unkown |
| HY-103547 | L-168049 | Antagonist | 99.94% | Unkown |
| HY-P1143A | [Des-His1,Glu9]-Glucagon amide TFA | Antagonist | 98.36% | Unkown |
| HY-P1141A | GLP-1(9-36)amide TFA | Antagonist | 98.61% | Unkown |
| HY-112679 | GLP-1 receptor agonist 2 | Agonist | 98.70% | Unkown |
| HY-P10032 | NN1177 | Agonist | 99.54% | Unkown |
| HY-P3102 | GLP-1(32-36)amide | 98.44% | Unkown | |
| HY-50675 | GRA Ex-25 | Inhibitor | 99.07% | Unkown |
| HY-141840 | GLP-1R modulator C5 | Modulator | 99.81% | Unkown |
| HY-50159 | Glucagon receptor antagonist-3 | Antagonist | 99.78% | Unkown |
| HY-P11237 | Enicepatide | Agonist | 98.16% | Unkown |
| HY-P10019 | Pegsebrenatide | Agonist | 95.50% | Unkown |
| HY-P5815 | GLP-1 (1-36) amide (human, rat) | 98.10% | Unkown | |
| HY-P10031 | SAR441255 | Agonist | 99.84% | Unkown |
| HY-50158 | Glucagon receptor antagonist-2 | Antagonist | 99.23% | Unkown |
| HY-P3617 | Glucagon (22-29) | Agonist | 98.12% | Unkown |
| HY-141842 | GLP-1R modulator L7-028 | Modulator | 99.47% | Unkown |
| HY-148212 | GLP-1R agonist 17 | Agonist | 99.82% | Unkown |
| HY-P10031A | SAR441255 TFA | 99.93% | Unkown | |
| HY-172811 | DA-302168S | Agonist | 98.01% | Unkown |
| HY-116854 | NNC 92-1687 | Antagonist | 98.74% | Unkown |
| HY-13443B | Exendin-4-Lys-azide TFA | Agonist | 99.84% | Unkown |
| HY-145632A | Pemvidutide TFA | Antagonist | 98.07% | Unkown |
| HY-P1145 | Glucagon-like peptide 1 (1-37), human | Agonist | 99.70% | Unkown |
| HY-P5815A | GLP-1 (1-36) amide (human, rat) TFA | 98.02% | Unkown | |
| HY-148844 | GCGR antagonist 2 | Antagonist | 98.17% | Unkown |
| HY-P3622 | (Ser8)-GLP-1 (7-36) amide, human | Agonist | 99.10% | Unkown |
| HY-141839 | GLP-1R modulator C16 | Modulator | 98.67% | Unkown |
| HY-153476A | GIP/GLP-1 dual receptor agonist-1 sodium | Agonist | 98.33% | Unkown |
| HY-P10032A | NN1177 TFA | Agonist | 99.22% | Unkown |
| HY-P3491 | Pegloxenatide | Agonist | 90.00% | Unkown |
| HY-P1543 | Exendin-3 | Antagonist | 99.89% | Unkown |
| HY-P1228 | HAEGTFT | 98.81% | Unkown | |
| HY-119739 | Skyrin | Antagonist | 97.0% | Unkown |
| HY-108795B | [Gly8]-GLP-1(7-37) acetate | Agonist | 99.11% | Unkown |
| HY-P4146B | Survodutide sodium | Agonist | / | Unkown |
| HY-124803 | GPCR modulator-1 | Modulator | / | Unkown |
| HY-P1224 | HAEGTFTSDVS | 98.62% | Unkown | |
| HY-P1231 | GTFTSDVSKQMEEEAVRLFIEWLKNGGPSSGAPPPS | 99.03% | Unkown | |
| HY-116819A | VU0453379 hydrochloride | Modulator | 99.0% | Unkown |
| HY-P1223 | Exendin-3/4 (59-86) | 98.19% | Unkown | |
| HY-P1227 | SDV-Exendin-3/4 | 95.96% | Unkown | |
| HY-P1225 | {Val1}-Exendin-3/4 | 99.45% | Unkown | |
| HY-P2497 | Exendin (5-39) | Antagonist | 99.43% | Unkown |
| HY-P1143 | [Des-His1,Glu9]-Glucagon amide | Antagonist | 99.32% | Unkown |
| HY-P5074 | GRPP (human) | Agonist | 98.94% | Unkown |
| HY-147622 | GLP-1R agonist 9 | Agonist | / | Unkown |
| HY-P1226 | HAEGTFTSD | Agonist | 98.48% | Unkown |
| HY-P10341 | ZP3022 | Agonist | 98.00% | Unkown |
| HY-144035 | GLP-1R agonist 4 | Agonist | 98.26% | Unkown |
| HY-P1229 | FTSDVSKQMEEEAVRLFIEWLKNGGPSSGAPPPS | 98.01% | Unkown | |
| HY-142162A | (S,R)-LSN3318839 | Control | 98.25% | Unkown |
| HY-P11274 | Zenagamtide | Agonist | / | Unkown |
| HY-128781 | Glucagon receptor antagonist-5 | Antagonist | / | Unkown |
| HY-138996 | GLP-1 receptor agonist 8 | Agonist | / | Unkown |
| HY-P0211 | [Ac-Tyr1,D-Phe2]GRF 1-29, amide (human) | Antagonist | / | Unkown |
| HY-128103 | Glucagon receptor antagonist-7 | Antagonist | / | Unkown |
| HY-P4843 | Gastric Inhibitory Polypeptide (6-30) amide (human) | / | Unkown | |
| HY-P3616 | Human glucagon-like peptide-1-(7-36)-Lys(Biotin) amide | / | Unkown | |
| HY-172673 | GLP-1R agonist 31 | Agonist | / | Unkown |
| HY-P11275 | TC4 | Agonist | / | Unkown |
| HY-P11818 | GIPR/GLP-1R/GCGR agonist-1 | / | Unkown | |
| HY-129657 | GLP-1 receptor agonist 4 | Agonist | / | Unkown |
| HY-P5578A | A8SGLP-1 TFA | Agonist | / | Unkown |
| HY-P3542 | Des His1, Glu8 Exendin-4 | Antagonist | / | Unkown |
| HY-P4503 | (D-His1)-Exenatide | Control | / | Unkown |
| HY-P3053 | Helospectin I | / | Unkown | |
| HY-P1144A | Oxyntomodulin (bovine, porcine) TFA | Agonist | / | Unkown |
| HY-P11487 | UTG-4 | Agonist | / | Unkown |
| HY-P5578 | A8SGLP-1 | Agonist | / | Unkown |
| HY-P3608 | [Des-His1,Glu9] Glucagon | Antagonist | / | Unkown |
| HY-P4459 | (Des-Gly2)-Exenatide | Control | / | Unkown |
| HY-P3539 | Exendin-4 (3-39) | / | Unkown | |
| HY-129658 | TT-OAD2 free base | Agonist | / | Unkown |
| HY-13443F | Exendin 4, biotin labeled | Agonist | / | Unkown |
| HY-P10337 | OXM-7 | Agonist | / | Unkown |
| HY-144135 | GLP-1R agonist 7 | Agonist | / | Unkown |
| HY-177156 | Glucagon receptor antagonist-8 | Antagonist | / | Unkown |
| HY-P2880 | PHI-27 (porcine) | / | Unkown | |
| HY-P3050 | Helospectin II | Inhibitor | / | Unkown |
| HY-P11279 | TC2 | Agonist | / | Unkown |
| HY-P11044 | GEP12 | Agonist | / | Unkown |
| HY-P5161 | FC382K10W15 | Agonist | / | Unkown |
| HY-107129 | MK-3577 | Antagonist | / | Unkown |
| HY-P3621 | Biotinyl-Glucagon (1-29), human, bovine, porcine | / | Unkown | |
| HY-P1160A | Bay 55-9837 TFA | / | Unkown | |
| HY-P0212 | Neuropeptide Y, porcine | Agonist | / | Unkown |
| HY-144133 | GLP-1R agonist 5 | Agonist | / | Unkown |
| HY-120401 | Glybuzole | Activator | / | Unkown |
| HY-P0212A | Neuropeptide Y, porcine TFA | / | Unkown | |
| HY-181709 | TPM003 | Agonist | / | Unkown |
| HY-159696A | ISIS 449884 sodium | Inhibitor | / | Unkown |
| HY-D3173 | TP-α | Modulator | / | Unkown |
| HY-159696B | ISIS 449884 sodium scrambled negative control | Inhibitor | / | Unkown |
| HY-153476 | GIP/GLP-1 dual receptor agonist-1 | Agonist | / | Unkown |
| HY-171851 | GLP-1R agonist 32 | Agonist | / | Unkown |
| HY-P11881 | IUB288 | Agonist | / | Unkown |
| HY-169707 | GCGR antagonist 3 | Antagonist | / | Unkown |
| HY-12525B | LGD 6972 ammonium | Antagonist | / | Unkown |
| HY-P2625S1 | GLP-2(3-33) (Leu-13C6,15N) TFA | Agonist | / | Unkown |
| HY-13443S | Exendin-4 (Leu-13C6,15N) TFA | / | Unkown | |
| HY-129656 | GLP-1 receptor agonist 3 | Agonist | / | Unkown |
| HY-144134 | GLP-1R agonist 6 | Agonist | / | Unkown |
| HY-P4672 | (Met(O)27)-Glucagon (1-29) (human, rat, porcine) | / | Unkown | |
| HY-P3101A | GLP-1(28-36)amide TFA | / | Unkown | |
| HY-P11880 | LY3324954 | Agonist | / | Unkown |
| HY-159696 | ISIS 449884 | Inhibitor | / | Unkown |
| HY-106559 | Sorbinicate | Inhibitor | / | Unkown |
| HY-P3102A | GLP-1(32-36)amide TFA | / | Unkown | |
| HY-144136 | GLP-1R agonist 8 | Agonist | / | Unkown |
| HY-144033 | GLP-1R agonist 1 | Agonist | / | Unkown |
| HY-172836S | GLP-1 receptor agonist 17-d3 | Agonist | / | Unkown |
| HY-P5161A | FC382K10W15 TFA | Agonist | / | Unkown |
| HY-180445 | Glucagon receptor antagonist-10 | Antagonist | / | Unkown |
| HY-12525A | LGD-6972 sodium | Antagonist | / | Unkown |
| HY-125824A | Danuglipron tromethamine | Agonist | / | Unkown |
| HY-12735 | SCH 900822 | Antagonist | / | Unkown |
| HY-160281 | CCD-2 | / | Unkown | |
| HY-180446 | Glucagon receptor antagonist-11 | Antagonist | / | Unkown |
| HY-180444 | Glucagon receptor antagonist-9 | Antagonist | / | Unkown |
| HY-118914 | Glucagon receptor antagonist inactive control | Control | / | Unkown |
Bioactive MoleculesInhibitory Antibodies
(3)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-P990013 | Gulgafafusp alfa | Inhibitor | 95.481% | Unkown |
| HY-P991099 | Anti-GLP1R Antibody | Inhibitor | 97.19% | Unkown |
| HY-P992006 | Anti-Glucagon Antibody | Inhibitor | / | Unkown |
Compound Screening Libraries
Virtual Screening
Customize Your Library
Drug Screening Service